Thus, taken together, the evidence indicates that IDH mutations in glioma may represent a different category, i.e., beneficial mutations, resulting from an aberrant cellular response that counteracts glioma progression, even though the mechanism by which transformed cells acquire this type of mutations necessitates further investigation. This evidence concerns the gene IDH2 and glioma.